Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded at StockNews.com

StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a hold rating to a buy rating in a research report released on Friday morning.

Other equities research analysts have also issued research reports about the company. Chardan Capital reissued a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. HC Wainwright restated a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $298.09.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $237.97 on Friday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company has a fifty day simple moving average of $258.73 and a 200-day simple moving average of $255.23. The stock has a market cap of $30.69 billion, a P/E ratio of -90.83 and a beta of 0.32. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the prior year, the company earned $1.15 EPS. The firm’s revenue was down 33.3% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals will post -2.21 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total value of $439,752.00. Following the transaction, the chief marketing officer now owns 15,705 shares in the company, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,122 shares of company stock worth $2,540,455. 1.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Eventide Asset Management LLC boosted its position in Alnylam Pharmaceuticals by 157.9% during the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after purchasing an additional 137,333 shares during the period. Los Angeles Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after purchasing an additional 135,829 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 92.5% during the second quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock worth $65,862,000 after purchasing an additional 130,482 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth about $29,111,000. Finally, Avoro Capital Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 33.3% in the second quarter. Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $97,200,000 after buying an additional 100,000 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.